Serum concentrations of soluble adhesion molecules are related to degree of hyperglycemia and insulin resistance in patients with type 2 diabetes mellitus

被引:74
作者
Matsumoto, K
Sera, Y
Nakamura, H
Ueki, Y
Miyake, S
机构
[1] Sasebo Chuo Hosp, Dept Diabet & Metab, Nagasaki 8571195, Japan
[2] Sasebo Chuo Hosp, Dept Rheumatol, Nagasaki 8571195, Japan
关键词
type 2 diabetes mellitus; soluble adhesion molecule; insulin resistance; insulin tolerance test; multiple risk factors;
D O I
10.1016/S0168-8227(01)00296-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To investigate the relationships between serum concentrations of soluble adhesion molecules and hyperglycemia, insulin resistance, or other conventional risk factors in type 2 diabetes, we measured soluble intercellular adhesion molecule-1 (sICAM-1), vascular cell adhesion molecule-1 (sVCAM-1), E-selectin (sE-selectin), insulin sensitivity, and conventional risk factors in 150 Japanese type 2 diabetic patients without apparent diabetic macroangiopathy. High serum concentrations of sVCAM-1 and sE-selectin were observed in patients with type 2 diabetes. Serum concentrations of soluble adhesion molecules were not significantly influenced by sex, hypertension. dyslipidemia, or microangiopathy. Spearman correlation showed that sVCAM-1 concentrations correlated significantly with fasting plasma glucose (FPG), fasting C-peptide, and insulin sensitivity [K index of the insulin tolerance test (K-ITT)] (rho = 0.19, 0.23 and -0.23, respectively), Soluble E-selectin concentrations correlated significantly with body mass index (BMI), FPG, fasting C-peptide, insulin sensitivity, and triglyceride (rho = 0.33, 0.42, 0.26, -0.48, and 0.29, respectively). Multiple regression analysis showed that FPG, fasting C-peptide, and total cholesterol were independent factors that correlated with sVCAM-1 levels. BMI, FPG, and insulin sensitivity were independent factors that correlated with sE-selectin levels. Serum concentrations of sE-selectin significantly increased associated with clustering of conventional risk factors those obesity, hypertension, dyslipidemia, and current smoking (P < 0.01). Thus, sVCAM-1 and sE-selectin levels are related to both hyperglycemia and insulin resistance. Soluble E-selectin levels may be related to obesity, hyperglycemia, and insulin resistance and may reflect the presence of a multiple risk factor clustering syndrome. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:131 / 138
页数:8
相关论文
共 32 条
  • [1] Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
  • [2] 2-S
  • [3] Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM -: Effect of intensive insulin treatment
    Albertini, JP
    Valensi, P
    Lormeau, B
    Aurousseau, MH
    Ferrière, F
    Attali, JR
    Gattegno, L
    [J]. DIABETES CARE, 1998, 21 (06) : 1008 - 1013
  • [4] ESTIMATES OF INVIVO INSULIN ACTION IN MAN - COMPARISON OF INSULIN TOLERANCE-TESTS WITH EUGLYCEMIC AND HYPERGLYCEMIC GLUCOSE CLAMP STUDIES
    BONORA, E
    MOGHETTI, P
    ZANCANARO, C
    CIGOLINI, M
    QUERENA, M
    CACCIATORI, V
    CORGNATI, A
    MUGGEO, M
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1989, 68 (02) : 374 - 378
  • [5] Carter AM, 1997, DIABETIC MED, V14, P423, DOI 10.1002/(SICI)1096-9136(199706)14:6<423::AID-DIA421>3.3.CO
  • [6] 2-6
  • [7] Increased circulating intercellular adhesion molecule-1 levels in type II diabetic patients: The possible role of metabolic control and oxidative stress
    Ceriello, A
    Falleti, E
    Bortolotti, N
    Motz, E
    Cavarape, A
    Russo, A
    Gonano, F
    Bartoli, E
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1996, 45 (04): : 498 - 501
  • [8] COMINACINI L, 1995, DIABETOLOGIA, V38, P1122
  • [9] Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration, in NIDDM patients
    Cominacini, L
    Garbin, U
    Fratta Pasini, A
    Campagnola, M
    Davoli, A
    Foot, E
    Sighieri, G
    Sironi, AM
    Lo Cascio, V
    Ferrannini, E
    [J]. DIABETES, 1998, 47 (01) : 130 - 133
  • [10] De C.R., 1995, J CLIN INVEST, V96, P60